Program overview
Context
Indication: Recurrent or Metastatic Solid Tumors
Mechanism: Unknown
Modality: Unknown
Sponsor: Daiichi Sankyo
Operational Burden Signal
Ifinatamab deruxtecan
Ifinatamab deruxtecan is flagged as operational burden signal because public records show operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 0/5
Timeline: 1/5
Recruitment burden: 3/5
Results availability: 0/5
Program risk: 2/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT06330064 | https://clinicaltrials.gov/study/NCT07630974 | https://clinicaltrials.gov/study/NCT06362252
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT06330064 | Low Signal (RECRUITING) | long_recruitment_duration_signal | Low Signal | large_enrollment_target_signal | rare_population_signal | strict_eligibility_signal |
| NCT07630974 | Low Signal (RECRUITING) | None | Low Signal | None |
| NCT06362252 | Low Signal (RECRUITING) | long_recruitment_duration_signal | Low Signal | strict_eligibility_signal |